Rees S, Constantopoulos G, Barranger J A, Brady R O
Naunyn Schmiedebergs Arch Pharmacol. 1982 Jun;319(3):262-70. doi: 10.1007/BF00495876.
The trypanocidal drug suramin causes glycosaminoglycan and sphingolipid accumulation in the rat, thus simulating a mucopolysaccharidosis (Constantopoulos et al. 1980). In this paper we report on the extent and nature of the morphological changes that occur in the liver, kidneys, spleen, heart, lung and brain as a result of short or long term suramin administration. The first group of rats received a single intravenous injection of suramin (500 mg/kg) and was sacrificed 3-9 days after the injection. The second group received low doses of suramin (50-90 mg/kg) at 2-3 weekly intervals over 3 months. Samples of the above mentioned organs were processed for light and electronmicroscopy and the remainder of the tissue weighed and assayed for total protein, DNA and RNA content. In both groups of rats, suramin caused an abnormal enlargement of the spleen, kidney, lung and liver, splenomegaly being the most pronounced. The total protein, and DNA content did not alter in the treated rats, however, the RNA content of the spleen increased 100%, 9 days after injection and there was a small but consistent increase in RNA content of the liver, kidney and lung. Significant pathological changes were observed in these organs and also in the brain and heart. The changes were similar in many respects to the pathology seen in the lysosomal storage disorder, mucopolysaccharidosis and further support the proposition that the suramin treated rat might be a useful experimental animal model of the disease. Several mechanisms by which suramin might produce organomegaly in the rat are discussed.
杀锥虫药物苏拉明可导致大鼠体内糖胺聚糖和鞘脂蓄积,从而模拟黏多糖贮积症(康斯坦托普洛斯等人,1980年)。在本文中,我们报告了短期或长期给予苏拉明后,肝脏、肾脏、脾脏、心脏、肺和大脑中发生的形态学变化的程度和性质。第一组大鼠接受单次静脉注射苏拉明(500毫克/千克),并在注射后3 - 9天处死。第二组大鼠在3个月内每隔2 - 3周接受低剂量的苏拉明(50 - 90毫克/千克)。对上述器官的样本进行光镜和电镜处理,其余组织称重并测定总蛋白、DNA和RNA含量。在两组大鼠中,苏拉明均导致脾脏、肾脏、肺和肝脏异常肿大,脾肿大最为明显。处理后的大鼠总蛋白和DNA含量未发生改变,然而,注射后9天脾脏的RNA含量增加了100%,肝脏、肾脏和肺的RNA含量也有小幅但持续的增加。在这些器官以及大脑和心脏中均观察到显著的病理变化。这些变化在许多方面与溶酶体贮积症黏多糖贮积症中所见的病理相似,进一步支持了经苏拉明处理的大鼠可能是该疾病有用的实验动物模型这一观点。文中讨论了苏拉明可能导致大鼠器官肿大的几种机制。